By Suruchi Aggarwal, Associate Director – Diagnostics, Strand Life Sciences
Blood cancers such as leukemia, lymphoma, and multiple myeloma remain among the most complex diseases that clinicians deal with today. Unlike many other cancers that are often driven by one or two dominant genetic changes, blood cancers tend to involve multiple genetic abnormalities that exist simultaneously. This complexity makes it increasingly difficult to rely on a single genetic test to guide treatment decisions.
As a result, there is a growing shift toward a multi-modal genomics approach in blood cancer diagnosis, where different types of genetic tests are combined to build a more complete and clinically meaningful understanding of the disease.
The Genetic Complexity of Blood Cancer
At a fundamental level, every cancer begins with changes in a cell’s DNA. In blood cancers, however, these changes are rarely straightforward. Some appear as small “spelling mistakes” within genes, while others involve large sections of DNA being duplicated, deleted, or rearranged across chromosomes. In certain cases, genes can fuse together, creating abnormal signals that drive uncontrolled cell growth.
What makes blood cancer particularly challenging is that several of these genetic changes can exist together within the same patient. Two individuals with the same diagnosis may therefore have very different genetic profiles, directly affecting how their disease behaves and how they respond to treatment.
This variability is a key reason why a one-size-fits-all approach to blood cancer genetic testing is no longer sufficient.
Also Read: Top 5 Signs and Symptoms of Hypothyroidism in Women
Limitations of Single Genetic Testing Methods
For many years, hospitals have relied on standard tools for genetic testing in blood cancer, but each method provides only a partial view.
Karyotyping offers a broad chromosomal overview and is useful for identifying large abnormalities such as missing or extra chromosomes or major rearrangements. However, it cannot detect smaller gene mutations that may still have a major clinical impact.
FISH (Fluorescence In Situ Hybridization) provides a more targeted approach by identifying specific known genetic changes. While faster and more precise in certain scenarios, it is limited to pre-selected abnormalities and may miss rare or unexpected mutations.
DNA sequencing tests go deeper by reading the genetic “letters” of selected cancer-related genes. These are highly effective for identifying small mutations that influence cancer growth and drug response. At the same time, they may not consistently detect larger structural changes such as gene rearrangements or chromosome-level alterations.
When used in isolation, these approaches can leave critical gaps. Research has shown that patients who appear “normal” on traditional testing may still carry hidden genetic abnormalities that affect disease aggressiveness and treatment response. Missing such changes can lead to incomplete risk assessment and missed treatment opportunities.
Why Multi-Modal Genomics Matters in Blood Cancer
A multi-modal genomics approach in blood cancer brings together multiple testing techniques to overcome these limitations. Rather than relying on a single method, it allows clinicians to examine the genome from different perspectives.
This combined view captures both the broader chromosomal landscape and the finer molecular details, creating a more complete and accurate understanding of the disease.
In practice, this approach is reshaping blood cancer diagnosis and treatment. Certain cancers are increasingly defined by their genetic characteristics rather than morphology alone, making comprehensive testing essential for accurate classification.
It also improves risk assessment. Specific genetic alterations are linked to aggressive disease, higher relapse risk, or resistance to therapy. Identifying these early helps guide treatment planning and monitoring strategies.
At the same time, modern oncology is increasingly dependent on targeted therapies. These treatments are designed to act on specific genetic abnormalities, and without comprehensive genomic testing in blood cancer, these mutations may go undetected—limiting access to effective therapies.
Also Read: The Role of Genetics in Type 1 Diabetes: What You Should Know
The Shift Toward Precision Medicine in Oncology
The growing adoption of multi-modal genomics reflects a broader transformation in healthcare—precision medicine. Instead of applying uniform treatment strategies, precision medicine focuses on tailoring care based on each patient’s unique biology.
Within this framework, integrated genomic testing plays a central role. It is no longer just about diagnosing disease, but about understanding it in depth and using that understanding to guide every stage of treatment.
Blood cancer care is steadily moving away from isolated testing methods toward a more integrated model. No single test can fully explain the complexity of these diseases, but when multiple genomic tools are used together, they provide a far more complete and actionable picture.
This shift is enabling more accurate diagnoses, better-informed treatment decisions, and improved alignment between disease biology and therapy—ultimately supporting better patient outcomes in modern oncology.
